Qualigen Therapeutics Provides Corporate Update For Q3 And To Date 2023
Qualigen Therapeutics Provides Corporate Update For Q3 And To Date 2023
Qualigen Therapeutics提供2023年第三季度及迄今爲止的公司最新情況
Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumors
Phase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024
Expect to select lead Pan-RAS inhibitor candidate for IND enabling studies in first quarter of 2024
在治療晚期或轉移性實體瘤的 QN-302 1 期臨床試驗的第一組中開始給三名患者給藥
1a期患者招募正在進行中;公司預計將在2024年第二季度分享有關安全性和初步療效的最新信息
預計將在2024年第一季度爲IND支持研究選擇潛在的Pan-ras抑制劑候選藥物
CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation,today provides a corporate update for the third quarter ending September 30, 2023 and to date:
加利福尼亞州卡爾斯巴德,2023年11月14日(GLOBE NEWSWIRE)——一家臨床階段療法公司Qualigen Therapeutics, Inc.(納斯達克股票代碼:QLGN),專注於開發有可能被指定爲孤兒藥的成人和兒科癌症的治療方法,今天提供了截至2023年9月30日的第三季度及迄今爲止的公司最新情況:
Highlights...
亮...
登入免費觀看全文
登入/註冊